NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.
Specifically, Ambergen is licensing its 5-prime photocleavable biotin, a light-activated biomolecule, to SomaLogic. Terms of the deal were not disclosed.
"AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our Somascan platform," SomaLogic Chief Technology Officer Nick Saccomano said in a statement.
SomaLogic's Somascan and Somamer technologies were developed to achieve necessary sensitivity on a high-throughput proteomic quantitation platform. The Somascan technology uses Somamers, or Slow Off-rate Modified Aptamers, for the screening of dozens of patient samples simultaneously "allowing quantification of many specific proteins in a multiplexed, high-throughput manner," the company said.
Last month, SomaLogic inked a deal with Novartis for use of its proteomics technologies for Novartis' drug discovery and development efforts.